RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 134 filers reported holding RIGEL PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $6,487 | +14.3% | 4,383 | +12.0% | 0.00% | – |
Q4 2023 | $5,674 | -44.4% | 3,913 | -58.6% | 0.00% | -100.0% |
Q3 2023 | $10,212 | -16.3% | 9,456 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $12,198 | -2.3% | 9,456 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $12,482 | -22.7% | 9,456 | -12.1% | 0.00% | 0.0% |
Q4 2022 | $16,142 | +29.6% | 10,761 | +2.0% | 0.00% | 0.0% |
Q3 2022 | $12,451 | +490.9% | 10,552 | +465.8% | 0.00% | – |
Q2 2022 | $2,107 | -94.0% | 1,865 | -84.1% | 0.00% | -100.0% |
Q1 2022 | $35,076 | -72.2% | 11,731 | -75.4% | 0.00% | -50.0% |
Q4 2021 | $126,220 | -20.1% | 47,630 | +9.5% | 0.00% | 0.0% |
Q3 2021 | $157,945 | -1.6% | 43,511 | +17.7% | 0.00% | 0.0% |
Q2 2021 | $160,450 | -6.0% | 36,970 | -25.9% | 0.00% | -33.3% |
Q1 2021 | $170,740 | +1.4% | 49,924 | +3.8% | 0.00% | 0.0% |
Q4 2020 | $168,322 | +42.1% | 48,092 | -2.5% | 0.00% | +50.0% |
Q3 2020 | $118,414 | +12.6% | 49,339 | -14.2% | 0.00% | 0.0% |
Q2 2020 | $105,192 | +17.5% | 57,482 | +0.2% | 0.00% | 0.0% |
Q1 2020 | $89,510 | -29.8% | 57,378 | -3.7% | 0.00% | 0.0% |
Q4 2019 | $127,529 | +57.8% | 59,593 | +37.9% | 0.00% | +100.0% |
Q3 2019 | $80,805 | -40.5% | 43,211 | -17.0% | 0.00% | -50.0% |
Q2 2019 | $135,895 | +1.6% | 52,067 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $133,812 | +16.7% | 52,067 | +4.4% | 0.00% | 0.0% |
Q4 2018 | $114,706 | -28.3% | 49,872 | 0.0% | 0.00% | -33.3% |
Q3 2018 | $160,089 | -99.9% | 49,872 | 0.0% | 0.00% | +50.0% |
Q2 2018 | $141,137,000 | -13.2% | 49,872 | +8.5% | 0.00% | 0.0% |
Q1 2018 | $162,645,000 | +124056.5% | 45,945 | +36.4% | 0.00% | 0.0% |
Q4 2017 | $131,000 | -68.1% | 33,686 | -79.2% | 0.00% | -33.3% |
Q3 2017 | $411,000 | +61.2% | 161,824 | +73.5% | 0.00% | +50.0% |
Q2 2017 | $255,000 | -17.5% | 93,287 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $309,000 | +120.7% | 93,287 | +58.9% | 0.00% | +100.0% |
Q4 2016 | $140,000 | -37.5% | 58,726 | -3.8% | 0.00% | -50.0% |
Q3 2016 | $224,000 | +47.4% | 61,049 | -10.2% | 0.00% | +100.0% |
Q2 2016 | $152,000 | +7.8% | 67,993 | 0.0% | 0.00% | 0.0% |
Q1 2016 | $141,000 | -30.9% | 67,993 | +1.2% | 0.00% | -50.0% |
Q4 2015 | $204,000 | +24.4% | 67,183 | +1.0% | 0.00% | +100.0% |
Q3 2015 | $164,000 | +97.6% | 66,503 | +156.8% | 0.00% | 0.0% |
Q2 2015 | $83,000 | -68.1% | 25,898 | -64.4% | 0.00% | -50.0% |
Q1 2015 | $260,000 | +49.4% | 72,762 | -4.9% | 0.00% | +100.0% |
Q4 2014 | $174,000 | +48.7% | 76,503 | +137.0% | 0.00% | 0.0% |
Q2 2014 | $117,000 | -58.8% | 32,275 | -56.0% | 0.00% | -50.0% |
Q1 2014 | $284,000 | +35.9% | 73,280 | 0.0% | 0.00% | +100.0% |
Q4 2013 | $209,000 | -20.2% | 73,280 | 0.0% | 0.00% | -50.0% |
Q3 2013 | $262,000 | +60.7% | 73,280 | +50.4% | 0.00% | +100.0% |
Q2 2013 | $163,000 | – | 48,719 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.02% |